Brand K et al
Semaglutide, because it was originally developed for diabetes, can be a good option for people who also need to manage their blood sugar levels
For instance, a study found that semaglutide 1.0 mg once weekly plus basal insulin significantly reduced mean HbA1c (a measure of long-term blood sugar control) compared to insulin when taken over 26 weeks [10]
Thus, we need more treatment options. The authors also point out that Wegovy may provide added benefits by addressing the comorbidities commonly seen in people with MASH, such as cardiovascular disease and obesity, a cluster of conditions known as Its definitely exciting to have another therapeutic, said Kim
Archives of Dermatology , 1977
Customs and further payments up to $1,200 are needed to release them (U.S